gian piero reverberi - overview of the diabetes - e-health 6.6.14
TRANSCRIPT
Overview of the Diabetes
Care Market Journée e-Health
Gian Piero Reverberi
Diabetes is a very large and growing problem worldwide
Many pharmacological innovations have been and will be introduced in
the future to address the needs of patients with Diabetes
Despite these innovations, Insulin will remain an important ammunition
in the hands of HCP to treat patients with diabetes
In addition to the significant pharmacological innovations, innovative
delivery systems and devices dramatically helped patients with
diabetes managing their life and their disease.
Significant future opportunties lie in the development of technologies
that can continue simplifying patients life, while supporting the
electronic transfer and elaboration of information for an integrated
disease management system
Executive Summary
Diabetes is a very large and growing problem worldwide
Many pharmacological innovations have been and will be introduced in
the future to address the needs of patients with Diabetes
Despite these innovations, Insulin will remain an important ammunition
in the hands of HCP to treat patients with diabetes
In addition to the significant pharmacological innovations, innovative
delivery systems and devices dramatically helped patients with
diabetes managing their life and their disease.
Significant future opportunties lie in the development of technologies
that can continue simplifying patients life, while supporting the
electronic transfer and elaboration of information for an integrated
disease management system
Executive Summary
Number of people with diabetes by region, 2013
Source: international diabetes federation
Diabetes is a huge and growing problem,
and the costs to society are high and escalating.
Prevalence of overweight and obesity in seleced countries
Sassi, F et al. 2009 The obesity Epidemic: analysis of past and projected
Future trends in Selected OECD Countries
Diabetes is a very large and growing problem worldwide
Many pharmacological innovations have been and will be
introduced in the future to address the needs of patients with
Diabetes
Despite these innovations, Insulin will remain an important ammunition
in the hands of HCP to treat patients with diabetes
In addition to the significant pharmacological innovations, innovative
delivery systems and devices dramatically helped patients with
diabetes managing their life and their disease.
Significant future opportunties lie in the development of technologies
that can continue simplifying patients life, while supporting the
electronic transfer and elaboration of information for an integrated
disease management system
Executive Summary
Evolution of Diabetes treatment for Type 2 patients
Time Time
Animal Insulin
Human Insulin
Insulin Analogs
GLP1 B cells insulin secretion
Sulfonylurea
Metformin
Alfa glucosidade inhibitors
TZD (Insulin resistance)
DPP IV Inhibitors Enzyme responsible
for degradation of GLP1
SGL 2 Inhibitors Prevent Reabsorption
of filtered glucose
47%
38%
7%
0%
7%
36%
33%
12%
16%
3%
Insulin
DPP IV Inhibitors
GLP 1
SGL 2 Inhibitors
TZD
2013
17 million Patients 2022
26 million Patients
Evolution of treatment in USA, EU5 and Japan – 2013 - 2022 (Sulfonylurea, Metformin and Alfa glucosidate inhibitor excluded)
Datamonitor Healthcare forecast - 2014
Diabetes is a very large and growing problem worldwide
Many pharmacological innovations have been and will be introduced in
the future to address the needs of patients with Diabetes
Despite these innovations, Insulin will remain an important
ammunition in the hands of HCP to treat patients with diabetes
In addition to the significant pharmacological innovations, innovative
delivery systems dramatically helped patients with diabetes managing
their life and their disease.
Significant future opportunties lie in the development of technologies
that can continue simplifying patients life, while supporting the
electronic transfer and elaboration of information for an integrated
disease management system
Executive Summary
67%
8%
25%
0%
70%
6%
17%
8%
Basal
Mix
Rapid
Insulin+GLP1
Evolution of Insulin treatment in USA, EU5 and Japan – 2013 - 2022 N. Of Patients
2013
8 million Patients
Datamonitor Healthcare forecast - 2014
2022
10 million Patients
Diabetes is a very large and growing problem worldwide
Many pharmacological innovations have been and will be introduced in
the future to address the needs of patients with Diabetes
Despite these innovations, Insulin will remain an important ammunition
in the hands of HCP to treat patients with diabetes
In addition to the significant pharmacological innovations,
innovative delivery systems and devices dramatically helped
patients with diabetes managing their life and their disease.
Significant future opportunties lie in the development of technologies
that can continue simplifying patients life, while supporting the
electronic transfer and elaboration of information for an integrated
disease management system
Executive Summary
Innovation in Insulin delivery
Diabetes is a very large and growing problem worldwide
Many pharmacological innovations have been and will be introduced in
the future to address the needs of patients with Diabetes
Despite these innovations, Insulin will remain an important ammunition
in the hands of HCP to treat patients with diabetes
In addition to the significant pharmacological innovations, innovative
delivery systems and devices dramatically helped patients with
diabetes managing their life and their disease.
Significant future opportunties lie in the development of
technologies that can continue simplifying patients life, while
supporting the electronic transfer and elaboration of information
for an integrated disease management system
Executive Summary
“….the use of modern information and
communication technologies to meet needs of
citizens, patients, healthcare professionals,
healthcare providers, as well as policy makers"
http://europa.eu/
European Community definition of E-health
Information for
patients
Communication
among patients
Information from
patients to
stakeholders
Communication
between patients
and
stakeholders
Greater patient demand for
more interactive, accessible,
high quality information
• Consumers are increasingly
leveraging the internet as a
source of information
18% CAGR from ‘98-’10
in amount of adults who
often look online for health
information
• Greater amount of health care
information is available to
consumers
• Patient-to-patient
information increasing Professional-to-patient
information increasing
• Online community for people with
life changing conditions
• More than 250’000 members
• More than 2000 conditions
• Platform for collecting and sharing
detailed real world, outcome-
based patient data
• Leading health portal in the US
• More than 80 million unique visitors per month
• Offers health advice, symptom checklist, drug information and community
• Remote monitoring
programs and
technologies
• Bluetooth devices
• Smartphone applications
• Blood pressure cuffs send
readings directly to your PC
• Eg: Blood glucose meter
seamlessly connects to the
iPhone
Examples of information and communication among HC
players
Technology is changing the way healthcare is delivered
Smartphone
applications
Computing
power
Connectivity
Remote
monitoring
and
Management
Data analytics
Electronic
records and
coding
Technological innovation Healthcare Delivery
Diabetes Care
Disease management
Systems
Health information exchange in current diabetes
care devices
Connectivity available No connectivity Connectivity available
100 % use Lancing devices – Glucose meters
95% use Insulin pens & syringes
Patients diagnosed with diabetes Patients on Insulin
5% use insulin pumps
Diabetes is a very large and growing problem worldwide
Many pharmacological innovations have been and will be introduced in
the future to address the needs of patients with Diabetes
Despite these innovations, Insulin will remain an important ammunition
in the hands of HCP to treat patients with diabetes
In addition to the significant pharmacological innovations, innovative
delivery systems and devices dramatically helped patients with
diabetes managing their life and their disease.
Significant future opportunties lie in the development of technologies
that can continue simplifying patients life, while supporting the
electronic transfer and elaboration of information for an integrated
disease management system
Executive Summary
Back up
0
5
10
15
20
25
0
1
2
3
4
5
6
7
8
1958 62 66 70 74 78 82 86 90 94 98 02 06 10
Nu
mb
er
with
Dia
be
tes (
Mill
ion
s)
Perc
enta
ge w
ith D
iabete
s
Year
Percentage with Diabetes
Number with Diabetes
Number and Percentage of U.S. Population with Diagnosed Diabetes,
1958–2010
CDC’s Division of Diabetes Translation. National Diabetes Surveillance System available at http://www.cdc.gov/diabetes/statistics
Age-adjusted Prevalence of Obesity and Diagnosed
Diabetes Among U.S. Adults Aged 18 Years or Older
Obesity (BMI ≥30 kg/m2)
Diabetes
1994
1994
2000
2000
No Data <14.0% 14.0%–17.9% 18.0%–21.9% 22.0%–25.9% 26.0%
No Data <4.5% 4.5%–5.9% 6.0%–7.4% 7.5%–8.9% >9.0%
CDC’s Division of Diabetes Translation. National Diabetes Surveillance System available at http://www.cdc.gov/diabetes/statistics
2010
2010
Diabetes has become an epidemic, primarily driven by
lifestyle changes (projections appear conservative)
International Diabetes Foundation: Diabetes Atlas
0
2'000
4'000
6'000
8'000
10'000
12'000
14'000
16'000
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Insulin
DPP IV Inhibitors
GLP 1
SGL 2 Inhibitors
TZD
Expected Revenues of Diabetes care treatment in USA, EU5 and Japan (Sulfs, Matformin and Alfa glucosidate inhibitor excluded)
USD Millions
Datamonitor Healthcare forecast - 2014
0
1'000'000
2'000'000
3'000'000
4'000'000
5'000'000
6'000'000
7'000'000
8'000'000
9'000'000
10'000'000
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Insulin
DPP IV Inhibitors
GLP 1
SGL 2 Inhibitors
TZD
Expected number of patients on Diabetes care treatment in USA, EU5 and Japan (Sulfs, Matformin and Alfa glucosidate inhibitor excluded)
Datamonitor Healthcare forecast - 2014
0
2'000
4'000
6'000
8'000
10'000
12'000
14'000
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Basal
Mix
Rapid
Insulin+GLP1
Forecasted Insulin revenues in USA, EU5 and Japan between 2013 and 2022 USD Millions
Datamonitor Healthcare forecast - 2014
70%
12%
18%
0%
69%
6%
7%
19%
Basal
Mix
Rapid
Insulin+GLP1
Evolution of revenues of different forms of insulins in USA, EU5 and Japan
2013 – 2022
USD Million
Datamonitor Healthcare forecast - 2014
0
1'000'000
2'000'000
3'000'000
4'000'000
5'000'000
6'000'000
7'000'000
8'000'000
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Basal
Mix
Rapid
Insulin+GLP1
Expected number of patients on different forms of Insulin in USA, EU5
and Japan
Datamonitor Healthcare forecast - 2014